Advancing First-in-Class Gene Therapies for Inherited Retinal Diseases

Company overview

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company’s mission is to design therapies to address the underlying genetic causes of severe retinal disorders that deliver durable vision improvement for patients.

Our pipeline includes seven adeno-associated virus (AAV)-based gene therapy assets, alongside a small-molecule therapy for large, underserved vision disorders. Opus has one FDA-approved product and has multiple programs in late-stage clinical development. Opus is executing a strategy centered on regulatory rigor, capital efficiency, and disciplined clinical development.

Maci, NMNAT1 patient with Mom Jenna

The Opus team

Opus is led by a seasoned management team with deep experience in ophthalmology, gene therapy, drug development and commercialization, and is supported by leading institutional investors and strategic partners.

Our mission at Opus is to restore and preserve vision for patients who have had few or no treatment options. As our programs advance, we are focused on translating scientific breakthroughs into therapies that can make a lasting difference in people’s lives, from rare inherited retinal diseases to common vision conditions that affect millions of patients worldwide.

– George Magrath, M.D., Chief Executive Officer of Opus Genetics